Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19, at its facility near Houston, Texas.
AMI Awarded $2M Grant from Florida Department of Commerce to Deploy Smart Manufacturing Lab
TALLAHASSEE, FL – Advanced Manufacturing International (AMI) has been awarded a $2M grant